Incredibly honored to be a recipient of a Conquer Cancer, the ASCO Foundation Career Development Award for our biomarker research in #SCLC. Forever grateful to mentors Nasser Hanna Christine Lovly, MD, PhD, FASCO & fierce pt advocate Jill Feldman for your guidance & support! IU Simon Comprehensive Cancer Center SmallCellSMASHERS

Thrilled to share this exciting study ⁦Nature Medicine⁩. Largest integrative analysis of #sotorasib efficacy biomarkers to date. Grateful to all co- investigators and the Amgen team for their hard work and most of all to our patients. ⁦MD Anderson Cancer Center⁩ #KRAS #NSCLC

WGS strikes again! enable MRD detection at ultra sensitive level, overcoming LoD ~100ppm of WES ➡️ ctDNA clearance during NAC 👉🏻 pCR Many❓remain: tissue requirement? how to account for tumor evolution? role of incorporating other markers? #ctDNA #ASCO2025

Why are there intronic reads in your bulk RNA-seq data? You're not alone—it's common, and the reasons are more layered than you think. Let’s break it down. 🧵

The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma in ESMO Open. Actionable targets in 46% of STS, specific subgroups with higher prevalence. WGS-informed therapy in 14% of cases. esmoopen.com/article/S2059-…

A first-in-class EGFR-directed KRAS G12V selective inhibitor cell.com/cancer-cell/fu…

Analysis of MARIPOSA JTO & JTO CRR comparing 1L lazertinib and osimertinib in #EGFR NSCLC. PFS 18.5m with lazertinib vs 16.6m with osimertinib (HR 0.98), RR 83% vs 85%, DOR 16.6m vs 16.8m, OS HR 1.00 - similar tox (laz more rash, osi more diarrhea). jto.org/article/S1556-…

Fidelity of Next-Generation Sequencing to Predict Human Epidermal Growth Factor 2 Overexpression Across Solid Tumors. Co-authored by Mya Tran. Read full article. brnw.ch/21wU4vg

Fantastic keynote fireside chat with 2024-2025 ASCO President Dr. Robin Zon (ASCO) & Nabil Adra at the IU Simon Comprehensive Cancer Center #ASCOReview25 on access, knowledge, and support to drive knowledge to action to build a better future for our patients and their families facing cancer.

A friendly, funny, and fierce debate on the timing of IO for resectable NSCLC: ⭐️neoadj Greg Durm vs ⭐️periop Rohan Maniar vs ⭐️adjuvant Misty Dawn Shields Never a dull moment at a IU ASCO Debate! 🏀 IU Simon Comprehensive Cancer Center #ASCO25 Indiana Pacers Dallas Mavericks NEW YORK KNICKS

#PrecisionMed 2025- Dr. Schneider discussed Clinical Utility at IU ASCO25 Review #ASCO25 ✅ Many targets w real activity ➡️ enroll pts on trials! (KRAS, MTAP etc) ✅AI assisted path (TROP2 NMR) ❌ctDNA MRD/dynamics: ?OS ❌MCED: suboptimal LOD for agnostic approach More 2 come!

What are "omics"? A good schematic cell.com/neuron/fulltex… could add epigenomics, immunomics, microbiomics, glycomics, exposomics, etc

Characterization of adenosquamous NSCLC and carcinosarcoma from The Shields Lab now JTO & JTO CRR. Actionable alterations (including METex14, EGFR, KRAS G12C, ALK, RET) seen in 37% of adenosquamous and in 17% of carcinosarcoma samples. jto.org/article/S1556-…

Comparison of EGFR NSCLC transformed to #SCLC vs de novo SCLC Lung Cancer Journal. OS shorter with transformed SCLC esp with high neuroendocrine marker expression. In transformed SCLC, OS with chemo-immunotherapy superior to chemo +/- TKI (15.4m vs 8.5m). lungcancerjournal.info/article/S0169-…

1/ I stopped trying to keep up with every new *Seq method— and my career got better. Here’s why that mindset shift matters.

Congrats Dr.Schneider! 👏🏻Bryan P. Schneider Schneider Lab IU Simon Comprehensive Cancer Center “Clinical trials are vehicles through which discovery becomes care” BSP New hope in bringing more equitable, precision-driven trials to serve our communities #IUPrecisionGenomics medicine.iu.edu/news/2025/08/i…

Be sure to attend #DCLung25 - Saturday, October 4th in Washington DC: a one-day IASLC endorsed lung cancer conference with experts like Dr. Misty Shields Misty Dawn Shields, who will discuss first line treatment for SCLC - and maintenance! Register today! medstarhealth.org/dclung25

How common is rebiopsy after progression on targeted therapy for NSCLC? Report Clinical Lung Cancer included 148 pts with EGFR, ALK, and ROS1 NSCLC post TKI and 53% had rebiopsy - 47% tissue, 33% liquid, 20% both. Biopsy gave new information for 40% of pts. clinical-lung-cancer.com/article/S1525-…